Detalles de la búsqueda
1.
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.
Cancer
; 128(21): 3775-3783, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36101004
2.
The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Int J Cancer
; 139(1): 153-63, 2016 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26910568
3.
Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse.
J Clin Med
; 12(19)2023 Sep 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37834840
4.
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.
J Clin Oncol
; 41(17): 3135-3148, 2023 06 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36854071
5.
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
J Nucl Med
; 59(3): 502-508, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28887399
6.
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.
J Clin Oncol
; 29(24): 3286-92, 2011 Aug 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-21768459
Resultados
1 -
6
de 6
1
Próxima >
>>